Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

In the phase 3 ALINA study published recently in the New England Journal of Medicine, adjuvant Alecensa ... MSD's $25 billion immunotherapy Keytruda (pembrolizumab) alongside chemotherapy before ...

full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for ...

CME activities, cases, challenges, videos, and more teaching and learning tools from the New England Journal of Medicine.

MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics ... them has been featured in the journal Science and the biotech's ...

A team of researchers from the Keck School of Medicine of USC has unlocked the details of a cellular pathway that triggers ...

Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In a multicenter, prospective ...

Few procedures have gone through a decade of practice-changing clinical trials as impressive as thrombectomy for stroke. Beginning in 2015 with multiple trials showing a benefit with thrombectomy ...